Halozyme Therapeutics (HALO) Tops Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $69.67 +0.99%
Revenue Growth %: +23.1%
Financial Fact:
Interest and other income, net: 334K
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +23.1%
Financial Fact:
Interest and other income, net: 334K
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of ($0.23), $0.01 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $33.8 million versus the consensus estimate of $31.76 million.
GUIDANCE:
Halozyme Therapeutics sees FY2017 revenue of $115-130 million, versus the consensus of $132.6 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- Carnival shares drop despite earnings beat on weak guidance
- BofA lists top 5 themes driving next $1tn in incremental semi sales
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
